잠시만 기다려 주세요. 로딩중입니다.

Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas

Annals of Surgical Treatment and Research 2018년 95권 6호 p.303 ~ 311
 ( Ha Su-Min ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery

 ( Hwang Shin ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
 ( Park Jin-Young ) - Cbs Bioscience Inc
 ( Lee Young-Joo ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
 ( Kim Ki-Hun ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
 ( Song Gi-Won ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
 ( Jung Dong-Hwan ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery
 ( Yu Yun-Suk ) - Cbs Bioscience Inc
 ( Kim Jin-Pyo ) - Cbs Bioscience Inc
 ( Lee Kyoung-Jin ) - Asan Medical Center Department of Fusion Medicine
 ( Tak Eun-Young ) - Asan Medical Center Department of Fusion Medicine
 ( Park Yo-Han ) - Inje University College of Medicine Inje University Busan Paik Hospital Department of Surgery
 ( Lee Sung-Gyu ) - University of Ulsan College of Medicine Asan Medical Center Department of Surgery

Abstract

Purpose: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC prognosis.

Methods: The predictive powers of OncoHepa test and ADV score were validated in 35 patients who underwent curative hepatic resection for naive solitary HCCs ≤5 cm.

Results: Median tumor diameter was 3.0 cm. Tumor recurrence and patient survival rates were 28.6% and 100% at 1 year, 48.6% and 82.9% at 3 years, and 54.3% and 71.4% at 5 years, respectively. The site of first tumor recurrence was the remnant liver in 18, lung in 1, and the peritoneum in 1. All patients with HCC recurrence received locoregional treatment. OncoHepa test showed marginal prognostic significance for tumor recurrence and patient survival. ADV score at 4log also showed marginal prognostic difference with respect to tumor recurrence and patient survival. Combination of these 2 tests resulted in greater prognostic significance for both tumor recurrence (P = 0.046) and patient survival (P = 0.048).

Conclusion: Both OncoHepa test and ADV score have considerably strong prognostic power, thus individual and combined findings of OncoHepa test and ADV score will be helpful to guide postresection surveillance in patients with solitary HCCs ≤5 cm.

키워드

Recurrence; Survival; Prognosis; Genes
원문 및 링크아웃 정보
 
등재저널 정보